This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
International Cardiometabolic Expert To Join Race Oncology’s Scientific Advisory Board
- Race Oncology appoints Associate Professor Erin Howden to scientific advisory board
- Howden has researched adverse effects of chemotherapy on cardiovascular fitness of cancer patients
- Appointment aims to bring Race Oncology’s new formulation of bisantrene to patients sooner
Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients.
Clinical-stage biopharmaceutical company Race Oncology (ASX:RAC) has appointed Associate Professor Erin Howden, of the Baker Heart and Diabetes Institute in Melbourne, to its scientific advisory board. Read more here.